Gianni & Origoni
Client SatisfactionGianni & Origoni assists its healthcare clients in the broad range of matters that arise in the sector, including acquisitions, licences, IP disputes, antitrust issues and labour matters. Its clients include pharmaceutical and biotech and medical device companies and public healthcare companies. Rosario Zaccà, the lead of the healthcare and life sciences practice, is well-versed in corporate and M&A, commercial, private equity and joint venture matters with a multi-jurisdictional element. In March 2023, Andrea Gritti departed the firm for Portolano Cavallo.
Legal 500 Editorial commentary
Key clients
- Alchimia Sgr
- ArchiMed S.a.S
- Aspen
- Biofarma Group
- Fondazione Luigi Maria Monti, owner of Istituto Dermopatico dell’Immacolata (IDI – IRCCS)
- GE Medical System Italia
- Herbalife Italia
- Hippocrates Holding
- Isagro
- Leadiant Group
- Livanova
- Medac GmbH
- MSD
- Novartis AG / Novartis Farma
- Novo Nordisk
- Orthofix
- Pentaferte
- Polygon
- Sanofi Aventis
- Takeda Italia
- Sharon Laboratories
- Zambon Group
Work highlights
- Advised in the litigation before the TAR Lazio against the decree of 6 July 2022 by which the Minister of Health quantified the reimbursement following the breach of the expenditure ceiling for medical devices for the years 2015, 2016, 2017 and 2018 and the decisions by which the Regions quantified the amounts to be paid by individual companies.
- Advised Keensight Capital, one of the leading private equity managers dedicated to pan-European Growth Buyout1 investments, in the acquisition of a majority stake in Axxam, a leading innovative Partner Research Organization in the life sciences industry.
- Advised Panakès Partners sgr, Italy's leading venture capital firm in the life sciences sector, in setting up and launching the 'Purple' alternative investment fund, which reached hard cap at final closing with a fundraising of EUR 175 million.
Practice head
The lawyer(s) leading their teams.
Rosario Zaccà